Global Leading Market Research Publisher QYResearch announces the release of its latest report "Oncolytic Virus Therapies - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Oncolytic Virus Therapies market, including market size, share, demand, industry development status, and forecasts for the next few years. For oncologists, cancer researchers, and immunotherapy developers, the challenge of selectively destroying tumor cells while sparing healthy tissue has driven innovation in biological treatments. The global Oncolytic Virus Therapies market addresses this need through genetically modified viruses designed to selectively infect and destroy cancer cells. By replicating within tumor cells, these viruses induce cell lysis while simultaneously stimulating the immune system to combat cancer. This dual mechanism—direct oncolysis plus immune activation—offers clinical potential for specific tumor types and advances the field of cancer immunotherapy, particularly for solid tumors resistant to conventional treatments. The global market for Oncolytic Virus Therapies was estimated to be worth US$ 293 million in 2025 and is projected to reach US$ 427 million, growing at a CAGR of 5.6% from 2026 to 2032. This steady growth reflects continued clinical development and regulatory approvals for oncolytic virus platforms. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/6092693/oncolytic-virus-therapies Tumor-Selective Viral Lysis with Immune Activation Oncolytic Virus Therapies are a form of biological treatment using genetically modified viruses to selectively infect and destroy cancer cells. By replicating within tumor cells, the viruses induce cell lysis while stimulating the immune system to combat cancer. The technology focuses on viral targeting and safety optimization, offering clinical potential for specific tumor types and advancing the field of cancer immunotherapy. The mechanism of action involves tumor-selective replication due to defects in antiviral pathways (e.g., interferon response) common in cancer cells. Viral replication releases tumor-associated antigens, triggering systemic anti-tumor immune responses. Talimogene laherparepvec (T-VEC, Imlygic®) is the first FDA-approved oncolytic virus therapy for metastatic melanoma. Industry Segmentation: Virus Types & Applications The Oncolytic Virus Therapies market is segmented by viral origin and tumor type: Naturally Occurring Oncolytic Virus Therapies: Unmodified viruses with inherent tumor selectivity, including reovirus, coxsackievirus, and Newcastle disease virus. These serve as platforms for further engineering. Genetically Modified Oncolytic Virus Therapies: Engineered viruses with enhanced tumor selectivity, armed with therapeutic transgenes (GM-CSF, cytokines), and improved safety profiles. A leading oncolytic virus developer recently reported Phase II data for a GM-CSF-armed adenovirus in bladder cancer. Application Segments Solid Tumors: Melanoma, glioblastoma, head and neck cancer, bladder cancer, and pancreatic cancer represent the primary focus due to localized administration feasibility. A major cancer center reported that oncolytic virus injection combined with checkpoint inhibitors improved response rates in cold tumors. Non-Solid Tumors: Hematologic malignancies represent a smaller segment but emerging research explores oncolytic virus applications for leukemia and lymphoma. Technology Developments & Market Trends Over the past six months, several advancements have shaped the market. Combination therapy with immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4) has shown synergistic effects, converting cold tumors to hot. Intravenous delivery platforms are under development to enable treatment of metastatic disease beyond local injection. Armed oncolytic viruses expressing bispecific T-cell engagers (BiTEs) or cytokines enhance anti-tumor immunity. The trend toward combination immunotherapies drives clinical trial activity for oncolytic viruses. Manufacturing scale-up for GMP-grade clinical and commercial supply remains a technical challenge. Regulatory pathways for oncolytic virus products are maturing, with FDA and EMA guidance updates. Regional Market Dynamics North America leads the oncolytic virus therapies market, driven by FDA approvals (T-VEC), strong clinical trial infrastructure, and cancer immunotherapy investment. The United States dominates with significant R&D activity. Europe follows closely, with strong oncolytic virus research in the UK, Germany, and Switzerland, and EMA regulatory pathways. Asia-Pacific is the fastest-growing region, with expanding clinical development, government support for biotech innovation, and growing oncology research in China, Japan, South Korea, and Australia. Competitive Landscape Key players include AMGEN, Shanghai Sunway Biotech, Daiichi Sankyo, Calidi Biotherapeutics, Replimune, Sibiono, Binhui Biopharm, Tasly, Sinopharm, Biottt, and Sinorda. Market Segmentation The Oncolytic Virus Therapies market is segmented as below: By Company AMGEN Shanghai Sunway Biotech Daiichi Sankyo Calidi Biotherapeutics Replimune Sibiono Binhui Biopharm Tasly Sinopharm Biottt Sinorda Segment by Type Naturally Occurring Oncolytic Virus Therapies Genetically Modified Oncolytic Virus Therapies Segment by Application Solid Tumors Non-Solid Tumors Exclusive Industry Outlook Looking ahead, the convergence of oncolytic virus therapy technology with combination immunotherapy, intravenous delivery, and armed transgenes represents a transformative growth opportunity. Development of systemically deliverable, tumor-targeting viral vectors will expand addressable patient populations. Integration with CAR-T and TCR-T cell therapies may enhance solid tumor efficacy. Additionally, the expansion of manufacturing capacity and streamlined regulatory pathways will accelerate commercialization. The ability to offer oncolytic virus therapies that combine tumor selectivity, immune activation, and favorable safety profiles—supported by robust clinical data and scalable manufacturing—will define competitive differentiation. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp